Al-Modawat Specialized Medical (9594) fair value: what the stock is really worth
We calculate from audited financials what Al-Modawat Specialized Medical is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Al-Modawat Specialized Medical for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
31‑month range 3.09 SAR – 972,709 SAR · fair‑value band 3.35 SAR – 6.03 SAR · the 4.73 SAR price screens above the 4.46 SAR fair value. Dashed = 300-day average. As of Sep 13, 2026.
Al-Modawat Specialized Medical Company operates a general hospital in the Kingdom of Saudi Arabia. The company was founded in 2014 and is headquartered in Muhayil, Saudi Arabia.
Stock analysis
Al-Modawat Specialized Medical (9594) currently trades at 4.73 SAR, while our model-based Fair Value estimate is 4.46 SAR, implying the stock looks roughly 6.0% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 11.31 SAR per share, and 7 of the 15 models we run sit above the 4.73 SAR price.
Bear case: the Asset-Based group reads lowest at 0.8300 SAR, and 8 of the 15 models stay below the price. Evidence for this calculation is medium.
Scenario range: 3.35 SAR (bear) to 6.03 SAR (bull), the price of 4.73 SAR sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Al-Modawat Specialized Medical reported revenue of 122M SAR in FY2025 versus 40.8M SAR in FY2021, a compound +31.4%/yr. Reported net income was 19.0M SAR in FY2025.
Key figures
Market cap 374M SAR (≈ $99.6M) · P/E ratio 20.6 · P/S ratio 3.20 · EPS (TTM) 0.2300 SAR · Net margin 15.6% · Return on equity 18.8% · Return on assets (EBIT) 12.5% · Operating margin 11.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at 0% fair-value upside, at −6%, 9594 screens richer than that median.
Fair Value models
Bear 3.35 SARFair Value 4.46 SARBull 6.03 SAR
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 8 months old). Earnings retained since then (0.1626 SAR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+61.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.7%
’21
’22
’23
’24
’25
What shareholders gained per year (last 3 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
−22.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year−22.2%
Dividend (yield on the price)0.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−2% → 18%
Compare Al-Modawat Specialized Medical with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks
Beats the industry median on 8/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Bottom 25%
Fair Value upside−7% · Below median
Profitability
Return on equity (TTM)19% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)13% · Top 25%
Operating margin (TTM)11% · Above median
Growth and dividend
Revenue growth22% · Top 25%
Dividend yield (TTM)0.0% · Bottom 25%
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Al-Modawat Specialized Medical Fair Value". https://www.fairvalue-calculator.com/stock/9594
Frequently asked questions
Is Al-Modawat Specialized Medical (9594) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of 4.46 SAR versus a price of 4.73 SAR, about −6% upside (fairly valued).
What is the fair value of 9594?
Our model-based fair value for Al-Modawat Specialized Medical is 4.46 SAR (as of Sep 13, 2026), built from audited fundamentals. The current price: 4.73 SAR.
What is the quality score of 9594?
Al-Modawat Specialized Medical has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Al-Modawat Specialized Medical (9594)?
Our model-based price target is the fair value of 4.46 SAR (as of Sep 13, 2026) from 15 valuation models. Cautious scenario 3.35 SAR, optimistic scenario 6.03 SAR. It is a calculation from audited fundamentals, not an analyst target.
What is the Al-Modawat Specialized Medical stock forecast for 2026?
Our models put fair value at 4.46 SAR, about −6% upside versus a price of 4.73 SAR (fairly valued). Cautious scenario 3.35 SAR, optimistic scenario 6.03 SAR. The calculation is refreshed regularly with new filings.
What is the revenue of Al-Modawat Specialized Medical (9594)?
Al-Modawat Specialized Medical reported trailing-twelve-month revenue of about 128M SAR (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Al-Modawat Specialized Medical (9594)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Al-Modawat Specialized Medical it is 4.46 SAR per share (as of Sep 13, 2026), against a price of 4.73 SAR. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is Al-Modawat Specialized Medical stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 9594 trades above its calculated fair value: price 4.73 SAR, fair value 4.46 SAR, a gap of about −6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 9594?
No. The price is what the market pays today (4.73 SAR); the fair value is what the company's own numbers justify (4.46 SAR). For Al-Modawat Specialized Medical the two are 0.2670 SAR per share apart. That gap is exactly why we show both numbers side by side.
How much is Al-Modawat Specialized Medical worth?
The market values Al-Modawat Specialized Medical at about 374M SAR (market capitalisation, as of Sep 13, 2026). Per share that is 4.73 SAR; our models calculate a fair value of 4.46 SAR per share.
What do the bullish and bearish scenarios say about 9594?
Our models span a range for Al-Modawat Specialized Medical: cautious scenario 3.35 SAR, base 4.46 SAR, optimistic 6.03 SAR per share (as of Sep 13, 2026, price 4.73 SAR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 9594?
Al-Modawat Specialized Medical trades at a price-to-earnings ratio of 20.6 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.46 SAR is built from several models across several years. Other multiples: P/B 1.1, P/S 0.8, EV/EBITDA 3.3.
How solid is the balance sheet of Al-Modawat Specialized Medical (9594)?
Balance-sheet figures for Al-Modawat Specialized Medical (as of Sep 13, 2026): return on equity 18.8%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
Which stocks are comparable to Al-Modawat Specialized Medical?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Al-Modawat Specialized Medical stock attractive at the current price?
The data as of Sep 13, 2026: price 4.73 SAR, calculated fair value 4.46 SAR (−6%), Quality Score 44/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 9594 calculated?
We run Al-Modawat Specialized Medical through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4.46 SAR, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.6 % above its aggregate fair value. Al-Modawat Specialized Medical itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Al-Modawat Specialized Medical (9594)?
The closing price on Sep 14, 2026 was 4.73 SAR. Our model-based fair value is 4.46 SAR, about −6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Al-Modawat Specialized Medical right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of Al-Modawat Specialized Medical
How large is the market capitalisation of Al-Modawat Specialized Medical (9594)?
The market capitalisation of Al-Modawat Specialized Medical is 374M SAR (≈ $99.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Al-Modawat Specialized Medical (9594)?
The price-to-sales ratio of Al-Modawat Specialized Medical is 3.20 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Al-Modawat Specialized Medical (9594)?
Earnings per share at Al-Modawat Specialized Medical are 0.2300 SAR (price ÷ EPS = P/E 20.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Al-Modawat Specialized Medical (9594)?
The net margin of Al-Modawat Specialized Medical is 15.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Al-Modawat Specialized Medical (9594)?
The return on equity (ROE) of Al-Modawat Specialized Medical is 18.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Al-Modawat Specialized Medical (9594)?
On an EBIT basis the return on assets of Al-Modawat Specialized Medical is 12.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Al-Modawat Specialized Medical (9594)?
The operating margin of Al-Modawat Specialized Medical is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Al-Modawat Specialized Medical (9594)?
Revenue at Al-Modawat Specialized Medical is growing +21.7% versus a year earlier (3y avg +27.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Al-Modawat Specialized Medical (9594)?
Earnings per share at Al-Modawat Specialized Medical are growing −48.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Al-Modawat Specialized Medical (9594) generate?
The free cash flow of Al-Modawat Specialized Medical is −17.1M SAR (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Al-Modawat Specialized Medical (9594) carry?
The net debt of Al-Modawat Specialized Medical is 569K SAR (fiscal year 2024). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Al-Modawat Specialized Medical in the live analysis
One click puts Al-Modawat Specialized Medical on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
